Login / Signup

Development and multicenter validation of an LC-MS-based bioanalytical method for antisense therapeutics.

Yuchen SunShin-Ichiro NittaKosuke SaitoRyuta HosogaiKeiko NakaiRyoya GodaHisao ShimizuHisashi FujitaMasaaki KakehiKazuyuki MurataTakeru YamaguchiTakeshi OkuzonoShinichi YamaneMitsuhiko KawabataTakayuki MatsunumaKentaro TakaharaNoriko KatoMasaki YamadaTokuyuki YoshidaTakao InoueYoshiro Saito
Published in: Bioanalysis (2022)
Background: Many bioanalytical methods for antisense oligonucleotides (ASOs) using LC-MS have been reported. However, no data have been available on the reproducibility and robustness of a single bioanalytical method for ASOs. As such, in the current study, we evaluated the reproducibility and robustness of LC-MS-based bioanalytical methods for ASOs in multiple laboratories. Methods/Results: Seven independent laboratories were included in this study. Mipomersen was measured by ion-pairing LC-MS (IP-LC-MS) as a model ASO using different LC-MS. The validation results of calibration curve, accuracy, precision and selectivity met the criteria of conventional bioanalytical method validation guidelines using LC/GC-MS for drugs in all laboratories. Meanwhile, carryover (>20%) was detected in three laboratories. Conclusion: We first demonstrated the multicenter-validated IP-LC-MS bioanalytical method for ASOs. Our data showed that the method was sensitive, robust and reproducible. However, the occurrence of carryover should be carefully monitored in its future application.
Keyphrases
  • risk assessment
  • electronic health record
  • big data
  • machine learning
  • nucleic acid
  • double blind
  • clinical practice
  • data analysis